Oxazole-bridged combretastatin A analogues with improved anticancer properties (Q39746380)

14 September 2017

title

Oxazole-bridged combretastatin A analogues with improved anticancer properties (English)

1 reference

14 September 2017

4

1 reference

14 September 2017

Bernhard Biersack

1

1 reference

14 September 2017

Katharina Effenberger

series ordinal

2

1 reference

14 September 2017

Rainer Schobert

series ordinal

3

1 reference

14 September 2017

publication date

1 March 2010

1 reference

14 September 2017

1 reference

14 September 2017

volume

5

1 reference

14 September 2017

issue

3

1 reference

14 September 2017

page(s)

420-427

1 reference

In vitro metabolism study of combretastatin A-4 in rat and human liver microsomes.

14 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002/CMDC.200900477

7 January 2021

Medicinal chemistry of combretastatin A4: present and future directions.

1 reference

https://api.crossref.org/works/10.1002/CMDC.200900477

7 January 2021

Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling

1 reference

https://api.crossref.org/works/10.1002/CMDC.200900477

7 January 2021

The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells

1 reference

https://api.crossref.org/works/10.1002/CMDC.200900477

7 January 2021

Potent, orally active heterocycle-based combretastatin A-4 analogues: synthesis, structure-activity relationship, pharmacokinetics, and in vivo antitumor activity evaluation

1 reference

https://api.crossref.org/works/10.1002/CMDC.200900477

7 January 2021

Vascular disrupting agents

1 reference

https://api.crossref.org/works/10.1002/CMDC.200900477

7 January 2021

Pt(II) complexes of a combretastatin A-4 analogous chalcone: effects of conjugation on cytotoxicity, tumor specificity, and long-term tumor growth suppression

1 reference

https://api.crossref.org/works/10.1002/CMDC.200900477

7 January 2021

Oxidative metabolism of combretastatin A-1 produces quinone intermediates with the potential to bind to nucleophiles and to enhance oxidative stress via free radicals

1 reference

https://api.crossref.org/works/10.1002/CMDC.200900477

7 January 2021

Polyunsaturated fatty acids augment free radical generation in tumor cells in vitro

1 reference

https://api.crossref.org/works/10.1002/CMDC.200900477

7 January 2021

A simple method for the solubilisation of reduced NBT, and its use as a colorimetric assay for activation of human macrophages by gamma-interferon

1 reference

https://api.crossref.org/works/10.1002/CMDC.200900477

7 January 2021

Bid-induced conformational change of Bax is responsible for mitochondrial cytochrome c release during apoptosis

1 reference

https://api.crossref.org/works/10.1002/CMDC.200900477

7 January 2021

Synthesis and evaluation of analogs of (Z)-1-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)ethene as potential cytotoxic and antimitotic agents

1 reference

https://api.crossref.org/works/10.1002/CMDC.200900477

7 January 2021

Synthesis and biological evaluation of boronic acid containing cis-stilbenes as apoptotic tubulin polymerization inhibitors

1 reference

https://api.crossref.org/works/10.1002/CMDC.200900477

7 January 2021

Histone deacetylase inhibitors: signalling towards p21cip1/waf1.

1 reference

https://api.crossref.org/works/10.1002/CMDC.200900477

7 January 2021

Identifiers

DOI

10.1002/CMDC.200900477

1 reference

14 September 2017

1 reference